Skip to main content

Table 2 Patient-reported outcomes (PROs)

From: Electroacupuncture for thalidomide/bortezomib-induced peripheral neuropathy in multiple myeloma: a feasibility study

Measure

Time point

n

Mean (SD)

p value

p value

Paired t test

Non-parametric signed rank test

Mixed model analysis*

FACT/GOG-NTX †

Baseline

19

20.8 (9.6)

–

–

–

4 weeks

18

16.7 (9.4)

0.0114

0.018

0.0263

 

9 weeks

15

9.9 (5.6)

0.0009

<0.0001

<0.0001

 

13 weeks

15

13.2 (8.5)

0.0007

<0.0002

<0.0001

BPI-SF ‡

      

Pain

Baseline

18

25.4 (18.5)

–

–

–

severity

4 weeks

18

18.2 (16.4)

0.0048

0.0052

0.0056

 

9 weeks

16

15.1 (14.5)

0.0004

0.0001

<0.0001

 

13 weeks

16

17.6 (16.6)

0.004

0.0007

<0.0001

Pain

Baseline

18

25.4 (18.5)

–

–

–

interference

4 weeks

18

18.2 (16.4)

0.0048

0.0052

0.0056

 

9 weeks

16

15.1 (14.5)

0.0004

0.0001

<0.0001

 

13 weeks

16

17.6 (16.6)

0.004

0.0007

<0.0001

Worst pain in

Baseline

18

6.2 (3.5)

–

–

–

last 24 hours

4 weeks

18

3.8 (2.7)

0.0057

0.0049

0.0004

 

9 weeks

16

2.9 (2.1)

<0.0001

0.0002

<0.0001

 

13 weeks

15

3.6 (2.5)

<0.0001

0.0006

<0.0001

FACT-G §

      

Physical

Baseline

18

9.2 (6.1)

–

–

–

Well-being

4 weeks

18

7.2 (5.6)

0.3

0.4

0.3

 

9 weeks

14

5.0 (3.8)

<0.05

0.02

0.002

 

13 weeks

16

5.5 (4.3)

0.01

0.002

0.0004

Social/family

Baseline

19

20.5 (6.3)

–

–

–

Well-being

4 weeks

16

19.7 (6.3)

0.7

0.8

0.4

 

9 weeks

14

19.4 (8.5)

0.3

0.7

0.1

 

13 weeks

15

19.6 (7.0)

0.3

0.6

0.3

Emotional

Baseline

19

5.3 (5.5)

–

–

–

Well-being

4 weeks

18

4.4 (4.0)

0.5

0.6

0.5

 

9 weeks

16

3.8 (4.3)

0.4

0.3

0.2

 

1 month

16

4.1 (3.9)

0.3

0.4

0.2

Functional

Baseline

19

20.8 (6.7)

–

–

–

Well-being

4 weeks

17

19.7 (8.4)

0.07

0.09

<0.05

 

9 weeks

14

19.6 (7.0)

0.1

0.1

0.1

 

1 month

15

20.4 (8.9)

0.4

0.4

0.3

  1. *Mixed model analysis for time effect was performed for variables with four assessments.
  2. †Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity Scale.
  3. ‡Brief Pain Inventory – Short Form.
  4. §Functional Assessment of Cancer Therapy – General Scale.